Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future.

Related Articles

Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future.

Urologia. 2017 Aug 01;84(3):130-141

Authors: Del Bene G, Sternberg CN

Abstract
Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future.

PMID: 28623648 [PubMed - indexed for MEDLINE]

http://ift.tt/2sGur5f